<DOC>
	<DOCNO>NCT00799513</DOCNO>
	<brief_summary>This phase II multi-institutional trial explore safety efficacy lenalidomide monotherapy give maintenance therapy follow salvage chemo-immunotherapy patient relapse refractory chemosensitive diffuse large B-cell lymphoma</brief_summary>
	<brief_title>Trial Lenalidomide Given Maintenance Therapy Relapsed Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Patients older 65 year younger eligible high-dose chemotherapy autologous stem cell transplantation biopsy-proven diffuse large B-cell lymphoma relapse previous combination chemotherapy regimen ± rituximab , achieve least partial response second-line chemotherapy ( ICE DHAP/DHAOx MINE regimen ) + rituximab receive single-agent lenalidomide 25 mg daily 21 day 28 , maintenance treatment progression disease . Dose reduction study drug make case adverse event report correlate clinically appropriate . One-year progression free survival primary endpoint overall survival , response rate toxicity secondary endpoint . With null hypothesis ( P0 ) 1-year PFS 30 % , study consider satisfactory efficacy lenalidomide worth investigation P1 correspond 1-yr PFS 50 % ( absolute increase 20 % term 1-yr progression-free survival ) . Considering standard type I error ( α ) 0,05 power 80 % ( Type 2 error 20 % ) 47 patient necessary trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age &gt; 65 year Age &lt; 65 eligible highdose chemotherapy autologous stem cell transplantation Biopsyproven DLBCL relapse previous combination chemotherapy regimen ± rituximab PR CR secondline chemotherapy ( ICE DHAP/DHAOx MINE regimen ) + rituximab ECOG performance status score &lt; 4 Female childbearing potential ( FCBP ) must demonstrate practice proper contraception avoid pregnancy risk study least 28 day discontinuation study Male subject must agree practice proper contraception sexual contact female childbearing potential CNS involvement Prior ASCT TTP &lt; 6 month firstline therapy Use experimental drug secondline salvage chemotherapy Severe concomitant illness / medical condition ( e.g . impaired respiratory and/or cardiac function , uncontrolled diabetes mellitus ) Active infectious disease HIV , HBV HCV positivity Impaired liver function ( Bilirubin &gt; 2 x upper normal limit ; ALT/AST/GGT &gt; 3 x upper normal limit ) one month salvage chemotherapy conclusion Impaired renal function ( creatinine clearance &lt; 50 ml/min ) one month salvage chemotherapy conclusion Absolute neutrophil count ( ANC ) &lt; 1000/microL Platelet count &lt; 75.000 /mm3 Hemoglobin &lt; 9 g/dL Noncooperative behaviour noncompliance Psychiatric diseases condition might impair ability give inform consent Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>revlimid</keyword>
	<keyword>large B-cell lymphoma</keyword>
	<keyword>relapse</keyword>
</DOC>